Section 06 · Monograph
Pregabalin CR
Reviewed Nov 2026FDA label
Lyrica CRGabapentinoid · ER
- Forms
- ER tab: 82.5, 165, 330mg
- Dose
- DPN: 165-330mg | PHN: 165-660mg once daily after evening meal
- MOA
- Binds α2δ Ca2+ channel subunit
Indications
- Neuropathic pain associated with diabetic peripheral neuropathyFDA-labeled
- Postherpetic neuralgiaFDA-labeled
Mechanism of Action
- Binds the alpha-2-delta subunit of voltage-gated calcium channels, reducing release of excitatory neurotransmitters
Full Dosing
Adult / usual
- DPN: start 165mg once daily after the evening meal, increase to 330mg within 1 week as tolerated
- Postherpetic neuralgia: 165mg once daily, may increase to 330mg within 1 week and up to 660mg/day if needed
- Schedule V — taper gradually over at least 1 week
Renal
- Swallow whole; renal adjustment required (reduce dose for CrCl 30-60mL/min; not recommended below 30mL/min)
Contraindications
- Known hypersensitivity to pregabalin or its components (including angioedema)
Drug Interactions
- Opioids and other CNS depressants: additive sedation and respiratory depression
- Thiazolidinediones: additive edema and weight gain
Adverse Effects
- Dizziness and somnolence
- Peripheral edema and weight gain
- Angioedema
- Blurred vision, dry mouth
- Misuse potential (Schedule V)
Monitoring Parameters
- Renal function
- Weight and edema
- Respiratory status with CNS depressants
Pregnancy & Lactation
- May cause fetal harm based on animal data; limited human data
- Present in milk; breastfeeding not generally recommended